Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: Potential implications for future prophylaxis recommendations

References

• Lok A, McMahon BJ. AASLD practice guidelines: chronic hepatitis B. Hepatology 2001;34:1225–1241.
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Dusheiko GM, Schafer DF et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Int Med 1982;96:447–479.
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan PK, Hui Petal. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 2003;70:553–561.
   Google Scholar
• Yeo W, Zee B, Zhong S et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004;90:1306–1311.
   PubMed Web of Science ®Google Scholar
• Leaw SJ, Yen CJ, Huang WT, Chen TY, Su WC, Tsao CJ. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol 2004;83:270–275.
   PubMed Web of Science ®Google Scholar
• Lok AS, Liang RH, Chiu EK, Wong KL,, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Reports of a prospective study. Gastroenterology 1991;100:182–188.
   PubMed Web of Science ®Google Scholar
• Kumagai K, Takagi T, Nakamura S et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiologic study in Japan. Ann Oncol 1997;8\(Suppl. 1): 107–109.
   Google Scholar
• Markovic S, Drozina G, Vovk M, Fidler-Jenko M. Reactiva-tion of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 1999;29: 2925–2930.
   Google Scholar
• Cheng AL, Hsiung CA, Su IJ et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003;37:1320–1328.
   PubMed Web of Science ®Google Scholar
• Tsutsumi Y, Kawamura T, Saitoh S et al. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis virus reactivation in rituximab therapy. L,euk Lymph 2004;45:627–629.
   PubMed Web of Science ®Google Scholar
• Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61–68.
   PubMed Web of Science ®Google Scholar
• Stroffolini T, Andriani A, Bibas M, Barlattani A. Successful treatment with lamivudine for reactivated hepatitis B infection following chemotherapy for non-Hodgkin's lymphoma. Ann Hematol 2002;81:48–49.
   PubMed Web of Science ®Google Scholar
• Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002;100:391–396.
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan PK, Ho WM et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Chin Oncol 2004;22:927–934.
   PubMed Web of Science ®Google Scholar
• Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001;115:58–62.
   PubMed Web of Science ®Google Scholar
• Lau GK, Yiu HH, Fong DY et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients under-going chemotherapy. Gastroenterology 2003;125:1742–1749.
   PubMed Web of Science ®Google Scholar
• Lok A, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004;39:357–361.
   Google Scholar
• Sherman M, Bain V, Villeneuve JP et al. Management of Viral Hepatitis: A Canadian Consensus Conference 2004 www.hepatology.ca/cm/FileLib/ViralHepatitisCanadian Consensus2004.pdf.
   Google Scholar
• Tillmann HL, Wedemeyer H, Manns MP. Treatment of hepatitis B in special patient groups: hemodialysis, heart and renal transplantation, fulminant hepatitis, hepatitis B reactiva-tion. J Hepatol 2003;39(Suppl 1):206–211.
   Google Scholar
• Marusawa H, Imoto S, Ueda Y, Chiba T. Reactivation of latently infected hepatitis B virus in a leukemia patient with antibodies to hepatitis B core antigen. J Gastroenterol 2001;36:633–666.
   PubMed Web of Science ®Google Scholar
• Sekine R, Taketazu F, Kuroki M et al. Fatal hepatic failure caused by chemotherapy-induced reactivation of hepatitis B virus in a patient with hematologic malignancy. Int J Hematol 2000;71:256–268.
   PubMed Web of Science ®Google Scholar
• Ishiga K, Kawatani T, Suou T et al. Fulminant hepatitis B type B after chemotherapy in a serologically negative hepatitis B virus carrier with acute myelogenous leukemia. Int J Hematol 2001;73:115–118.
   PubMed Web of Science ®Google Scholar
• Iwai K, Tashima M, Itaoh M et al. Fulminant hepatitis B following bone marrow transplantation in a HbsAg negative, HBsAB positive recipient; reactivation of dormant virus during the reactivation period. Bone Marrow Transplant 2000;25:105–108.
   PubMed Web of Science ®Google Scholar
• Blanpain C, Knoop C, Delforge ML et al. Reactivation of hepatitis B after transplantation in patients with pre-existing anti-hepatitis B surface antigen antibodies: report on three cases and review of the literature. Transplantation 1998; 66:883–886.
   PubMed Web of Science ®Google Scholar
• Dickson RC, Everhart JE, Lake JR et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Trans-plantation Database. Gastroenterology 1997;113:1668–1674.
   Google Scholar
• Wachs ME, Amend WJ, Ascher NL et al. The risk of transmission of hepatitis B from HBsAg(- ), HBcAb( +), HBIg,M(-) organ donors. Transplantation 1995;59: 230–234.
   PubMed Web of Science ®Google Scholar
• Dodson SF, Bonham CA, Geller DA, Cacciarelli TV, Rakela J, Fung II. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999;68:1058–1061.
   PubMed Web of Science ®Google Scholar
• Lau JY, Bath VG, Davies SE et al. High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. Gastroenterology 1992;102:956 — 962.
   PubMed Web of Science ®Google Scholar
• Al Faraidy K, Yoshida EM, Davis JE, Vartanian RK, Anderson FH, Steinbrecher UP. Alteration of the dismal natural history of fibrosing cholestatic hepatitis secondary to hepatitis B virus with the use of lamivudine. Transplantation 1997;64:926–928.
   PubMed Web of Science ®Google Scholar
• Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 2004;83:769–774.
   Google Scholar